Clinical Trials

Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease

In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.

SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.

AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.

AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility

AbbVie has discontinued an ongoing phase 3 trial evaluating its antibody drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M) for the treatment of newly diagnosed glioblastoma (GBM), an aggressive type of brain cancer, owing to futility.

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes

Melior Pharmaceuticals I, a US-based mid-stage biopharma company, said that its insulin sensitizer, tolimidone (MLR-1023) has succeeded in a phase 2b trial in Type 2 diabetes mellitus (T2DM).

Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced positive results of an ex-U.S. proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED).

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Novartis today announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma announced that its hypertension and chronic kidney disease (CKD) drug Veltassa (patiromer) has met its primary endpoint in phase II Amber study.